Skip to main content
SpringerLink
Log in
Book cover

Cholinergic Basis for Alzheimer Therapy pp 170–182Cite as

Birkhäuser

Functional Cholinergic Receptor Sensitivity: The Role of Drug Probes

  • Chapter

Part of the book series: Advances in Alzheimer Disease Therapy ((AADT))

Abstract

Despite being one of the oldest and best known of the brain neurotransmitters, the central cholinergic system continues to be poorly understood functionally in humans. Elegant studies of the neuromuscular junction have helped elucidate many peripheral cholinergic mechanisms, but the central physiology is still shrouded in mystery, in part due to the elusive nature of acetylcholine itself and the lack of easily measurable metabolites.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aigner TG, Mitchell SJ, Aggleton JP, DeLong MR, Struble RG, Price DL, Wenk GL and Mishkin M (1987): Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 92:292–300.

    Article  Google Scholar 

  • Avissar S and Schreiber G (1989): Muscarinic receptor subclassification and G-proteins: Significance for lithium action in affective disorders and for the treatment of the extrapyramidal side effects of neuroleptics. Biol Psychiatry 25:94–112.

    Article  Google Scholar 

  • Bartus RT, Dean RL, Beer B and Lippa AS (1982): The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417.

    Article  Google Scholar 

  • Bartus RT and Johnson HR (1982): Short-term memory in the rhesus monkey: Disruption from the anti-cholinergic scopolamine. Science 217:401–417.

    Article  Google Scholar 

  • Beatty WW, Butters N and Janowsky DS (1986): Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav Neural Biol 45:196–211.

    Article  Google Scholar 

  • Block RI and Berchou R (1984): Alprazolam and lorazepam effects on memory acquisition and retrieval processes. Pharmacol Biochem Behav 20:233–241.

    Article  Google Scholar 

  • Block RI, DeVoe M, Stanley B, Stanley M and Pomara N (1985): Memory performance in individuals with primary degenerative dementia: Its similarity to diazepam-induced impairments. Exp Aging Res 11:151–155.

    Google Scholar 

  • Bondareff W, Mountjoy CQ and Roth M (1982): Loss of neurons of origin of the adrenergic projection to the cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 32:164–168.

    Article  Google Scholar 

  • Bonner TI (1989): New subtypes of muscarinic acetylcholine receptors. Trends Pharmacol Sci 10:11–15.

    Article  Google Scholar 

  • Bowen DM, Allen SJ, Benton JS, et al (1983): Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy and Alzheimer’s disease. J Neurochem 41:266–272.

    Article  Google Scholar 

  • Branconnier RJ, DeVitt DR, Cole JO and Spera KF (1982): Amitriptyline selectively disrupts verbal recall from secondary memory of the normal aged. Neurobiol Aging 3:55–59.

    Article  Google Scholar 

  • Broks P, Preston GC, Traub M, Poppleton P, Ward C and Stahl SM (1988): Modelling dementia: Effects of scopolamine on memory and attention. Neuropsychologia 26:685–700.

    Article  Google Scholar 

  • Buckley NJ, Bonner TI, Buckley CM and Brann MR (1989): Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 35:469–476.

    Google Scholar 

  • Callaway E, Halliday R, Naylor H and Schechter G (1985): Effects or oral scopolamine on human stimulus evaluation. Psychopharmacology 85:133–138.

    Article  Google Scholar 

  • Cawley RH, Post F and Whitehead A (1973): Barbiturate tolerance and psychological functioning in elderly depressed patients. Psychol Med 3:39–52.

    Article  Google Scholar 

  • Cross AJ, Crow TJ, Ferrier IN and Johnson JA (1986): The selectivity of the reduction of S2 receptors in Alzheimer-type dementia. Neurobiol Aging 7:3–1.

    Article  Google Scholar 

  • Davies P (1988): Neurochemical studies: An update on Alzheimer’s disease. J Clin Psychiatry 49 (Suppl. 5):23–28.

    Google Scholar 

  • Davies P, Katzman R and Terry RD (1980): Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 288:279–280.

    Article  Google Scholar 

  • Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC and Horvath TB (1987): Induction of depression with oxotremorine in patients with Alzheimer’s disease. Am J Psychiatry 144:468–471.

    Google Scholar 

  • Deutsch JA (1971): The cholinergic synapse and the site of memory. Science 174:783–794.

    Article  Google Scholar 

  • Drachman DA and Leavitt J (1974): Human memory and the cholinergic system. Arch Neurol 30:113–121.

    Article  Google Scholar 

  • Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F and Agid Y (1987): Cholinergic-dependent cognitive deficits in Parkinson’s disease. Ann Neurol 22:26–30.

    Article  Google Scholar 

  • Emery OB and Breslau LD (1989): Language deficits in depression: Comparisons with SDAT and normal aging. J Gerontol 44:M85–M92.

    Article  Google Scholar 

  • Eslinger PJ, Damasio AR, Benton AL and VanAUen M (1985): Neuropsychologic detection of abnormal mental decline in older persons. JAMA 253:670–674.

    Article  Google Scholar 

  • Flicker C, Serby M and Ferris SH (1990): Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology 100:243–250.

    Article  Google Scholar 

  • Francis PT, Palmer AM, Sims NR et al (1985): Neurochemical studies of early-onset Alzheimer’s disease: Possible influence on treatment. New Eng J Med 313:7–11.

    Article  Google Scholar 

  • Gil DW and Wolfe BB (1985): Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase. J Pharmacol Exp Ther 232:608–616.

    Google Scholar 

  • Glass RM, Uhlenhuth EH, Hartel FW, Matuzas W and Fischman MW (1981): Cognitive dysfunction and imipramine and outpatient depressives. Arch Gen Psychiatry 38:1048–1051.

    Article  Google Scholar 

  • Gottfries CG (1985): Alzheimer’s disease and senile dementia: Biochemical characteristics and aspects of treatment. Psychopharmacology 86:245–252.

    Article  Google Scholar 

  • Grober E, Buschke H, Kawas C and Fuld P (1985): Impaired ranking of semantic attributes in dementia. Brain Lang 26:276–286.

    Article  Google Scholar 

  • Grober E, Leipzig RM, Lipton RB, Wisniewski W, Schroeder M, Davies P, Ritter W and Buschke H (1989): Does scopolamine directly impair memory. J Cog Neurosci 1:327–335.

    Article  Google Scholar 

  • Honer WG, Prohovnik I, Smith G and Lucas LR (1988): Scopolamine reduces frontal cortex perfusion. J Cereb Blood Flow Metab 8:635–641.

    Article  Google Scholar 

  • Janowsky DS, Risch SC, Kennedy B, Ziegler M and Huey L (1986): Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release. Psychopharmacology 89:150–154.

    Article  Google Scholar 

  • Kopelman MD and Corn TH (1988): Cholinergic ‘blockade’ as a model for cholinergic depletion. Brain 111:1079–1110.

    Article  Google Scholar 

  • Krieg JC, Bossert S, Pirke K-M, vonZerssen D and Berger M (1987): The influence of the muscarinic agonist RS 86 on the cortisol system. Biol Psychiatry 22:573–582.

    Article  Google Scholar 

  • Kumar R, Mac DS, Gabrielli WF and Goodwin DW (1987): Anxiolytics and memory. A comparison of lorazepam and alprazolam. J Clin Psychiatry 48:158–160.

    Google Scholar 

  • Martin A (1987): Representation of semantic and spatial knowledge in Alzheimer’s patients: Implications for models of preserved learning in amnesia. J Clin Exp Neuropsychol 9:191–224.

    Article  Google Scholar 

  • Mash DC, Flynn DD and Potter LT (1985): Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science 228:1115–1117.

    Article  Google Scholar 

  • McMahon TF, Weiner M, Lesko L and Emm T (1987): Effects of age on antidepressant kinetics and memory in Fischer 344 rats. Pharmacol Biochem Behav 26:313–319.

    Article  Google Scholar 

  • Mesulam M-M, Mufson EJ and Rogers J (1987): Age-related shrinkage of cortically projecting cholinergic neurons: A selective effect. Ann Neurol 22:31–36.

    Article  Google Scholar 

  • Meyerhoff JL and Bates VE (1985): Combined treatment with muscarinic and nicotinic cholinergic antagonists slows development of kindled seizures. Brain Res 339:386–389.

    Article  Google Scholar 

  • Miller LL and Branconnier RJ (1983): Cannabis: Effects on memory and the cholinergic limbic system. Psychol Bull 93:441–456.

    Article  Google Scholar 

  • Mohs RC, Johns CA, Dunn DD, Sherman NA, Rosen WG and Davis KL (1986): Anticholinergic dementia as a model of alzheimer’s disease. In: Handbook for Clinical Memory Assessment, Poon LW, ed. Washington, D.C.: APA, pp. 403–408.

    Chapter  Google Scholar 

  • Molchan SE, Weingartner HJ, Lawlor BL, Martinez RA, Hill JL and Sunderland T (1991): Scopolamine-induced cognitive impairment in younger vs. older normal volunteers (Submitted).

    Google Scholar 

  • Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A and Murphy DL (1988a): Intravenous nicotine in Alzheimer’s disease: A pilot study. Psychopharmacology 95:171–175.

    Article  Google Scholar 

  • Newhouse PA, Sunderland T, Tariot PN, Weingartner H, Thompson K, Mellow AM, Cohen RM and Murphy DL (1988b): The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry 45:906–912.

    Article  Google Scholar 

  • Nürnberger Jr JI, Jimerson DC, Simmons-Ailing S, Tamminga C, Nadi NS, Lawrence D, Sitaram N, Gillin JC and Gershon ES (1983): Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and “well state” bipolar patients. Psychiatry Res 9:191–200.

    Article  Google Scholar 

  • Olds ME and Domino EF (1969): Comparison of muscarinic and nicotinic cholinergic agonists on self-stimulation behavior. J Pharmacol Exp Ther 166:189–204.

    Google Scholar 

  • Pandit SK, Dundee JW and Keilty SR (1971): Amnesia studies with intravenous premedication. Anaesthesia 26:421–428.

    Article  Google Scholar 

  • Patat A, Klein MJ and Hucher M (1987): Effects of single oral doses of clobazam, diazepam and lorazepam on performance tasks and memory. Eur J Clin Pharmacol 32:461–466.

    Article  Google Scholar 

  • Preston GC, Broks P, Traub M, Ward C, Poppleton P and Stahl SM (1988): Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology 95:208–215.

    Article  Google Scholar 

  • Rissenberg M and Glanzer M (1986): Picture superiority in free recall: The effects of normal aging and primary degenerative dementia. J Gerontol 41:64–71.

    Article  Google Scholar 

  • Schwarz RD, Bernabel AA, Spencer CJ and Pugsley TA (1990): Loss of muscarinic Ml receptors with aging in the cerebral cortex of fisher 344 rats. Pharmacol Biochem Behav 35:589–593.

    Article  Google Scholar 

  • Sitaram N, Nürnberger JI, Gershon ES and Gillin JC (1982): Cholinergic regulation of mood and REM sleep: Potential model and marker of vulnerability to affective disorder. Am J Psychiatry 139(5):571–576.

    Google Scholar 

  • Snodgrass JG and Corwin J (1987): Pragmatics of measuring recognition memory: Applications to dementia and amnesia. J Exp Psychol [Gen] 116:1–17.

    Google Scholar 

  • Sulkowski A (1980): Marihuana “high”: A model of senile dementia?. Perspectives Biol Med 209-214.

    Google Scholar 

  • Sunderland T, Molchan S, Martinez R, Vitiello B and Martin P (1990): Drug challenge strategies in Alzheimer’s disease: A focus on the scopolamine model. In: Alzheimer’s Disease: Current Research in Early Diagnosis, Becker RE and Gracobini E, ed. New York: Taylor and Francis, pp. 173–191.

    Google Scholar 

  • Sunderland T, Tariot P, Murphy DL, Weingartner H, Mueller EA and Cohen RM (1985): Scopolamine challenges in Alzheimer’s disease. Psychopharmacology 87:247–249.

    Article  Google Scholar 

  • Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA and Murphy DL (1987): Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: A dose-response study. Arch Gen Psychiatry 44:418–426.

    Article  Google Scholar 

  • Sunderland T, Tariot PN and Newhouse PA (1988): Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 13:371–389.

    Article  Google Scholar 

  • Sunderland T, Tariot PN, Weingartner H, Murphy DL, Newhouse PA, Mueller EA and Cohen RM (1986): Pharmacologic modelling of Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 10:599–610.

    Article  Google Scholar 

  • Sunderland T, Weingartner H, Cohen RM, Tariot PN, Newhouse PA, Thompson KE, Lawlor BA, and Mueller EA (1989): Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology 99:129–133.

    Article  Google Scholar 

  • Surichamorn W, Kim ON, Lee NH, Lai WS and El-Fakahany EE (1988): Effects of aging on the interaction of quinuclidinyl benzilate, N-methyl-scopolamine, pirenzepine, and gallamine with brain muscarinic receptors. Neurochem Res 13:1183–1191.

    Article  Google Scholar 

  • Summers WK, Jaouski LV, March QM, Tachiki K, Kling A (1986): Oral tetrahydroaminoacridine in long-term treatment of senile dementia of the Alzheimer type. New Eng J Med 315:1241–1245.

    Article  Google Scholar 

  • Troster AI and Beatty WW (1989): Effects of scopolamine on anterograde and remote memory in humans. Psychobiology 17:12–18.

    Google Scholar 

  • Vige X and Briley M (1988): Scopolamine induces upregulation of nicotinic receptors in intact brain but not in nucleus basalis lesioned rats. Neurosci Lett 88:319–324.

    Article  Google Scholar 

  • Watson M, Roeske WR and Yamamura HI (1988): Decreased muscarinic receptor density in the aged rat brain. Proc West Pharmacol Soc 31:61–65.

    Google Scholar 

  • Weingartner H, Grafman J, Boutelle W, Kaye W and Martin PR (1983): Forms of memory failure. Science 221:380–382.

    Article  Google Scholar 

  • Weingartner H, Sitaram N and Gillin JC (1979): The role of the cholinergic nervous system in memory consolidation. Bull Psychonom Soc 13:9–11.

    Google Scholar 

  • Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL and Kellar KJ (1986): Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res 371:146–151.

    Article  Google Scholar 

  • Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT and DeLong MR (1982): Alzheimer’s disease and senile dementia: Loss of neurons in the basal forebrain. Science 215:1237–1239.

    Article  Google Scholar 

  • Witkin JM, Gordon RK and Chiang PK (1987): Comparison of in vitro actions with behavioral effects of antimuscarinic agents. J Pharmacol Exp Ther 242:796–803.

    Google Scholar 

  • Wolkowitz OM, Weingartner H, Thompson K, Pickar D, Paul SM and Hommer DW (1987): Diazepam induced amnesia: A neuropharmacological model of an “organic amnestic syndrome”. Am J Psychiatry 144:25–29.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit on Geriatric Psychopharmacology and Unit on Cognitive Studies, LCS, National Institute of Mental Health, Bethesda, MD, USA

    Trey Sunderland, Susan Molchan, Ben Vitiello, Rick Martinez & Alex Martin

Authors
  1. Trey Sunderland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Molchan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ben Vitiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rick Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alex Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry School of Medicine, Southern Illinois University, Springfield, IL, 62794, USA

    Robert Becker

  2. Department of Pharmacology School of Medicine, Southern Illinois University, Springfield, IL, 62794, USA

    Ezio Giacobini

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sunderland, T., Molchan, S., Vitiello, B., Martinez, R., Martin, A. (1991). Functional Cholinergic Receptor Sensitivity: The Role of Drug Probes. In: Becker, R., Giacobini, E. (eds) Cholinergic Basis for Alzheimer Therapy. Advances in Alzheimer Disease Therapy. Birkhäuser, Boston, MA. https://doi.org/10.1007/978-1-4899-6738-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-6738-1_20

  • Publisher Name: Birkhäuser, Boston, MA

  • Print ISBN: 978-1-4899-6740-4

  • Online ISBN: 978-1-4899-6738-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation